Novartis (NYSE:NVS)‘s stock had its “neutral” rating reiterated by stock analysts at Nord/LB in a research note issued on Wednesday.

A number of other research analysts have also weighed in on NVS. Barclays lowered shares of Novartis from an “equal weight” rating to an “underweight” rating in a research note on Wednesday, October 25th. Zacks Investment Research raised shares of Novartis from a “sell” rating to a “hold” rating in a research note on Thursday, October 26th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Novartis in a research note on Tuesday, October 31st. Leerink Swann lifted their price target on shares of Novartis from $89.00 to $91.00 and gave the company a “market perform” rating in a research note on Monday, October 23rd. Finally, Bank of America lowered shares of Novartis from a “neutral” rating to an “underperform” rating in a research note on Wednesday, December 6th. Four analysts have rated the stock with a sell rating, eleven have assigned a hold rating and four have given a buy rating to the company’s stock. Novartis presently has an average rating of “Hold” and an average target price of $85.32.

Shares of Novartis (NYSE:NVS) opened at $83.11 on Wednesday. Novartis has a 1 year low of $69.53 and a 1 year high of $86.90. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.81 and a current ratio of 1.08. The company has a market cap of $196,226.09, a P/E ratio of 29.58, a PEG ratio of 2.63 and a beta of 0.73.

Novartis (NYSE:NVS) last issued its quarterly earnings data on Tuesday, October 24th. The company reported $1.29 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.25 by $0.04. The firm had revenue of $12.41 billion during the quarter, compared to analysts’ expectations of $12.21 billion. Novartis had a net margin of 13.73% and a return on equity of 15.77%. The business’s revenue for the quarter was up 2.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.23 earnings per share. research analysts expect that Novartis will post 4.76 earnings per share for the current year.

Several hedge funds have recently made changes to their positions in NVS. Atlantic Trust Group LLC raised its position in Novartis by 54.2% during the third quarter. Atlantic Trust Group LLC now owns 72,427 shares of the company’s stock worth $6,218,000 after acquiring an additional 25,452 shares in the last quarter. Parametric Portfolio Associates LLC increased its holdings in shares of Novartis by 9.4% in the third quarter. Parametric Portfolio Associates LLC now owns 1,719,039 shares of the company’s stock valued at $147,579,000 after purchasing an additional 148,197 shares during the last quarter. Steward Partners Investment Advisory LLC acquired a new position in shares of Novartis in the third quarter valued at $1,245,000. Coastline Trust Co increased its holdings in shares of Novartis by 8.0% in the third quarter. Coastline Trust Co now owns 20,970 shares of the company’s stock valued at $1,800,000 after purchasing an additional 1,560 shares during the last quarter. Finally, Garde Capital Inc. acquired a new position in shares of Novartis in the third quarter valued at $618,000. 10.85% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This story was published by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/12/27/novartis-nvs-earns-neutral-rating-from-nordlb.html.

Novartis Company Profile

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Analyst Recommendations for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.